D. E. Shaw & Co., Inc.
- SEC CIK
- 0001009207
- Latest filing
- Aug 14, 2026
KROS holding history
Keros Therapeutics, Inc. in every 13F filed by D. E. Shaw & Co., Inc., including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
KROS overviewAll 13F holders of KROSFull Q2 2026 holdings
- Shares (Q2 2026)
- 267,460
- Value
- $2.86M
- % of portfolio
- <0.1%
- Quarters held
- 13
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 267,460 | $2.86M | <0.1% | −242,148−47.5% | Reduced | Holders |
| Q1 2026 | 509,608 | $5.63M | <0.1% | −245,865−32.5% | Reduced | Holders |
| Q4 2025 | 755,473 | $15.4M | <0.1% | −575,952−43.3% | Reduced | Holders |
| Q3 2025 | 1,331,425 | $21.1M | <0.1% | +34,042+2.6% | Added | Holders |
| Q2 2025 | 1,297,383 | $17.3M | <0.1% | +34,253+2.7% | Added | Holders |
| Q1 2025 | 1,263,130 | $12.9M | <0.1% | +1,251,031+10,340.0% | Added | Holders |
| Q4 2024 | 12,099 | $191.5K | <0.1% | −174,189−93.5% | Reduced | Holders |
| Q3 2024 | 186,288 | $10.8M | <0.1% | +10,593+6.0% | Added | Holders |
| Q2 2024 | 175,695 | $8.03M | <0.1% | +156,821+830.9% | Added | Holders |
| Q1 2024 | 18,874 | $1.25M | <0.1% | +18,874 | New | Holders |
| Q2 2023 | 0 | $0 | 0.0% | −31,032−100.0% | Sold out | Holders |
| Q1 2023 | 31,032 | $1.33M | <0.1% | +31,032 | New | Holders |
| Q3 2022 | 0 | $0 | 0.0% | −21,056−100.0% | Sold out | Holders |
| Q2 2022 | 21,056 | $582.0K | <0.1% | +21,056 | New | Holders |
| Q2 2021 | 0 | $0 | 0.0% | −26,142−100.0% | Sold out | Holders |
| Q1 2021 | 26,142 | $1.61M | <0.1% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.